(EN) A Randomized, Phase ? Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer
ARTEMIDE-Gastric01
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
 SITE GLEN
|
Rilvegostomig avec fluoropyrimidine et trastuzumab deruxtecan versus trastuzumab, chimiothérapie et pembrolizumab
|
(EN) A Randomized, Phase ? Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan Versus Trastuzumab, Chemotherapy, and Pembrolizumab for the First Line Treatment of HER2-positive Gastric Cancer
ARTEMIDE-Gastric01
Actif en recrutement
|
CHU DE QUEBEC – UNIVERSITE LAVAL
HOPITAL DE L'ENFANT-JESUS
|
Rilvegostomig avec fluoropyrimidine et trastuzumab deruxtecan versus trastuzumab, chimiothérapie et pembrolizumab
|
(EN) A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
CCTG GA4
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Paclitaxel + Ramucirumab +/- Zanidatamab
|
(EN) A Randomized Phase II Study of Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Positive Advanced Gastroesophageal Adenocarcinoma
CCTG GA4
Actif en recrutement
|
CIUSSS DU NORD-DE-L'ILE-DE-MONTREAL
HOPITAL DU SACRE-COEUR-DE-MONTREAL
|
Paclitaxel + Ramucirumab +/- Zanidatamab
|
(EN) A Phase 2 Nonrandomized, Open-label, Multisite Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan in Participants With Gastrointestinal Cancers
MK-5909-005 (REJOICE-GI01)
Actif en recrutement
|
CENTRE HOSPITALIER DE L'UNIVERSITE DE MONTREAL
|
Raludotatug Deruxtecan
|
(EN) A Phase 3, Multicenter, Open-label, Randomized Study to Compare the Efficacy and Safety of MK-2870 Versus Treatment of Physician's Choice in 3L+ Advanced/Metastatic Gastroesophageal Adenocarcinoma (Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, and Esophageal Adenocarcinoma)
TroFuse-015
Actif en recrutement
|
CENTRE UNIVERSITAIRE DE SANTE MCGILL
SITE GLEN
|
Sacituzumab Tirumotecan (MK-2870) versus traitement ai choix du clinicien
|
